SLXN Company Profile and Key Details

SLXN has shown mixed momentum, gaining 5.66% over the past week and -36.36% over the past quarter, though year-to-date performance is up 16.67%. Short-term trend indicators are bullishly aligned (SMA20 5.33%, SMA50 -12.38%, SMA200 -72.38%). The stock’s 14-day RSI is 48.85 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.48% below its high and over 22.54% above its low. Average 10-day trading volume of 138.93 thousand shares is below the 3-month average of 239.74 thousand, indicating normal recent market interest.

Silexion Therapeutics Ltd. generated EPS of -$25.21 over the past year. Five-year average earnings growth is -286.09%. Wall Street analysts project EPS growth of 77.73% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 1614.29% upside. The low target suggests 1614.29% downside. The mean target is $6.00. This offers 1614.29% upside. Silexion Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by -75.61%. The prior quarter beat by -34.11%. Over the last six quarters, Apple has recorded several small beats. These include 37.14% in August 12, 2025.

Silexion Therapeutics Ltd. has 5.56 million shares outstanding. The public float is 5.56 million shares, elevated short interest at 2.41% of float. This equals 21.28 thousand shares. The short ratio is 0.3 days. Institutional investors hold 0.78% of the float. Insiders own 27.39%. Over the past six months, insider transactions show net selling. They sold 22.82 thousand shares across 1 transactions.

Silexion Therapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.15. This means the shares are trading below this model’s fair value.

The stock is currently within 5% of its 52-week low $0.34 and $77.70. With a market capitalization of about $146.44 thousand, Silexion Therapeutics Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.25). Key stats such as the average daily volume over the past year has been around 287.62 thousand shares, volume is running light vs its 52-week average. Headquartered in Jerusalem, TA, Silexion Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ilan Hadar, the company employs approximately 14 people and listed since August 16, 2024. Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors.

Silexion Therapeutics Ltd. trades at a P/E ratio of -0.01, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.27 trading at moderately above to book value. The P/FCF stands at -0.01, also above market averages.

Silexion Therapeutics Ltd. (NASDAQ:SLXN) shares are up 16.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Silexion Therapeutics Ltd. trading at a premium to the broader market with a P/E of -0.01. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.50, suggesting 1473.68% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-94.28% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Silexion Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by September 23, 2026, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -94.28%, reaching $0.02 by December 08, 2026, with a range of $0.00 to $4.60. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 09, 2027, within a range of $0.00 to $184.17.